Skip to content
Medium cut-off hemodialysis in multiple myeloma-associated cast nephropathy: A single-center experience
All contributors

Onconephrology contributor

Kumada, Hiromitsu

Primarily Anti-VEGF / TKI renal effects#38 of 47 recognized
  • #5 in Anti-VEGF / TKI renal effects
4
Clinical papers
636
Citations (iCite)
0 / 4
First / senior author
2016–2023
Active years

Output over time

Clinical corpus papers per year — peak 1 in 2016.

  • 2016: 1 paper
  • 2017: 1 paper
  • 2020: 1 paper
  • 2023: 1 paper
20162023

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Anti-VEGF / TKI renal effects4

Agents they study

Catalog agents whose clinical kidney literature lists Kumada among the leading contributors.

Lenvatinib3

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 37854758 (opens PubMed in a new tab)PMID 31720835 (opens PubMed in a new tab)PMID 27704266 (opens PubMed in a new tab)PMID 26500236 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.